يعرض 1 - 20 نتائج من 69 نتيجة بحث عن '"FIDELIO-DKD"', وقت الاستعلام: 0.51s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal

    المصدر: Perakakis, Nikolaos; Bornstein, Stefan R; Birkenfeld, Andreas L; Linkermann, Andreas; Demir, Münevver; Anker, Stefan D; Filippatos, Gerasimos; Pitt, Bertram; Rossing, Peter; Ruilope, Luis M; Kolkhof, Peter; Lawatscheck, Robert; Scott, Charlie; Bakris, George L; FIDELIO-DKD and FIGARO-DKD investigators (2024). Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis. Diabetes, Obesity & Metabolism, 26(1):191-200.

    وصف الملف: application/pdf

    Relation: https://www.zora.uzh.ch/id/eprint/255655/1/ZORA255655.pdf; info:pmid/37814928; urn:issn:1462-8902

  3. 3
    Academic Journal

    المساهمون: Medicine, School of Medicine

    المصدر: Publisher

    وصف الملف: application/pdf

    Relation: Kidney International; Bakris GL, Ruilope LM, Anker SD, et al. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int. 2023;103(1):196-206. doi:10.1016/j.kint.2022.08.040; https://hdl.handle.net/1805/40314

  4. 4
    Electronic Resource

    المصدر: Perakakis, Nikolaos; Bornstein, Stefan R; Birkenfeld, Andreas L; Linkermann, Andreas; Demir, Münevver; Anker, Stefan D; Filippatos, Gerasimos; Pitt, Bertram; Rossing, Peter; Ruilope, Luis M; Kolkhof, Peter; Lawatscheck, Robert; Scott, Charlie; Bakris, George L; FIDELIO-DKD and FIGARO-DKD investigators (2024). Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis. Diabetes, Obesity & Metabolism, 26(1):191-200.

  5. 5
    Academic Journal

    Relation: Filippatos, G., Anker, S. D., Agarwal, R., Ruilope, L. M., Rossing, P., Bakris, G. L., Tasto, C., Joseph, A., Kolkhof, P., Lage, A., Pitt, B., & FIGARO-DKD Investigators (2022). Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation, 145(6), 437–447. https://doi.org/10.1161/CIRCULATIONAHA.121.057983; http://hdl.handle.net/11268/11188

  6. 6
    Academic Journal

    Relation: Rossing, P., Filippatos, G., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Chan, J. C. N., Kooy, A., McCafferty, K., Schernthaner, G., Wanner, C., Joseph, A., Scheerer, M. F., Scott, C., & Bakris, G. L. (2022). Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. Kidney International Reports. 7(1), 36-45. https://doi.org/10.1016/j.ekir.2021.10.008; http://hdl.handle.net/11268/11187

  7. 7
    Academic Journal

    Relation: https://doi.org/10.2337/dc21-1944; Rossing, P., Burgess, E., Agarwal, R., Anker, S. D., Filippatos, G., Pitt, B., Ruilope, L. M., Gillard, P., MacIsaac, R. J., Wainstein, J., Joseph, A., Brinker, M., Roessig, L., Scott, C., Bakris, G. L., & FIDELIO-DKD. (2022). FinereNone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care, 45(4), 888-897. https://doi.org/10.2337/dc21-1944; http://hdl.handle.net/11268/11145

  8. 8
    Academic Journal

    Relation: https://doi.org/10.1681/ASN.2021070942; Agarwal, R., Joseph, A., Anker, S. D., Filippatos, G., Rossing, P., Ruilope, L. M., Pitt, B., Kolkhof, P., Scott, C., Lawatscheck, R., Wilson, D. J., Bakris, G. L., & FIDELIO-DKD Investigators (2022). Hyperkalemia Risk with FinereNone: Results from the FIDELIO-DKD Trial. Journal of the American Society of Nephrology, 33(1), 225–237. https://doi.org/10.1681/ASN.2021070942; http://hdl.handle.net/11268/11149

  9. 9
    Academic Journal

    Relation: Agarwal, R., Anker, S. D., Filippatos, G., Pitt, B., Rossing, P., Ruilope, L. M., Boletis, J., Toto, R., Umpierrez, G. E., Wanner, C., Wada, T., Scott, C., Joseph, A., Ogbaa, I., Roberts, L., Scheerer, M. F., & Bakris, G. L. (2022). Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 37(7), 1261–1269. https://doi.org/10.1093/ndt/gfab336; http://hdl.handle.net/11268/10567

  10. 10
    Academic Journal

    المساهمون: Medicine, School of Medicine

    المصدر: PMC

    وصف الملف: application/pdf

    Relation: European Journal of Heart Failure; Filippatos G, Pitt B, Agarwal R, et al. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail. 2022;24(6):996-1005. doi:10.1002/ejhf.2469; https://hdl.handle.net/1805/40758

  11. 11
    Academic Journal

    المساهمون: Medicine, School of Medicine

    المصدر: PMC

    مصطلحات موضوعية: CREDENCE, FIDELIO-DKD, Canagliflozin, Cardiorenal, Finerenone

    وصف الملف: application/pdf

    Relation: Nephrology Dialysis Transplantation; Agarwal R, Anker SD, Filippatos G, et al. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant. 2022;37(7):1261-1269. doi:10.1093/ndt/gfab336; https://hdl.handle.net/1805/40405

  12. 12
    Academic Journal

    المساهمون: Medicine, School of Medicine

    المصدر: PMC

    وصف الملف: application/pdf

    Relation: Diabetes, Obesity & Metabolism; Rossing P, Agarwal R, Anker SD, et al. Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial. Diabetes Obes Metab. 2022;24(1):125-134. doi:10.1111/dom.14558; https://hdl.handle.net/1805/40037

  13. 13
    Academic Journal

    المساهمون: DUKE-NUS MEDICAL SCHOOL

    المصدر: Scopus OA2021

    Relation: Filippatos, Gerasimos, Bakris, George L., Pitt, Bertram, Agarwal, Rajiv, Rossing, Peter, Ruilope, Luis M., Butler, Javed, Lam, Carolyn S. P., Kolkhof, Peter, Roberts, Luke, Tasto, Christoph, Joseph, Amer, Anker, Stefan D., FIDELIO-DKD Investigators. (2021-07-01). Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. Journal of the American College of Cardiology 78 (2) : 142-152. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jacc.2021.04.079; https://scholarbank.nus.edu.sg/handle/10635/232604

  14. 14
    Academic Journal

    المساهمون: Medicine, School of Medicine

    المصدر: PMC

    وصف الملف: application/pdf

    Relation: Kidney International Reports; Rossing P, Filippatos G, Agarwal R, et al. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. Kidney Int Rep. 2021;7(1):36-45. Published 2021 Oct 14. doi:10.1016/j.ekir.2021.10.008; https://hdl.handle.net/1805/40305

  15. 15
    Academic Journal
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20